Press Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard Mar 7, 2024 For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy Feb 1, 2024 Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 Jan 8, 2024 Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies vs. Wolverines Championship Game Dec 12, 2023 Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally Nov 14, 2023 Evofem Biosciences Announces Financial Results for the Third Quarter of 2023 Oct 24, 2023 Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023 Oct 13, 2023 Evofem to Participate in the Virtual Investor Ask the CEO Conference Sep 27, 2023 Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi Patents Expire Sep 11, 2023 Evofem Biosciences Successfully Amends S.P.A. with Institutional Investor Aug 22, 2023 Evofem Biosciences Signs Non-Binding Letter of Intent to Enable Listing on a National Stock Exchange Show 5102550100 per page«123456789…23»